For Researchers - Search Now For Contributors - Join Now

Leadership

Management Team

Christopher Ianelli

Christopher Ianelli, MD, PhD

Founder and Chief Executive Officer

Christopher Ianelli

Christopher Ianelli, MD, PhD

Founder and Chief Executive Officer

Chris conceptualized and founded iSpecimen in response to the precision medicine movement and the growing demand for biospecimens by life science researchers.  As CEO, he is responsible for the company’s growth, performance, and corporate direction.  Under his leadership, iSpecimen has become a dominant player in research sample procurement, recently developing and launching the industry’s first and only true marketplace platform connecting researchers with healthcare providers and biorepositories.

Prior to launching iSpecimen, Chris served as Managing Director at Leerink Partners (formerly Leerink Swann), a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm. At Leerink, Chris launched Health Insight Technologies, a healthcare informatics company that was spun out of the firm as Humedica and acquired by UnitedHealth Group in 2013.

Prior to Leerink, Chris was a co-founder and Managing Director of Boston Medical & Scientific Advisors, a healthcare investment research firm ultimately acquired by Leerink. He received both his Ph.D. in Immunology and his M.D. from Tufts University and completed his residency training, including a year as Chief Resident, in Pathology at Brigham & Women’s Hospital and Harvard Medical School.

Jill Mullan

Jill Mullan

Chief Operating Officer

Jill Mullan

Jill Mullan

Chief Operating Officer

Jill is responsible for ensuring operational excellence throughout the company. In this position, she oversees iSpecimen’s supply partner programs and operations, human resources, marketing, corporate communications, and corporate strategy. She is also responsible for ensuring regulatory compliance, privacy and security across the company’s operations.

Jill has over 25 years of experience in operational management, strategy, and marketing. Before joining iSpecimen, Jill ran a consulting business to help companies develop business and product strategies, raise funds, create brands, and launch new products. Prior to that, Jill was on the founding team and Director of Marketing at Storigen Systems, where she built and ran the company’s marketing organization, developed the company’s brand identity, and launched several successful products. She was also the Director of Product Marketing and Management at Avid Technology, managing the P&L for Avid’s $400M editing product line. Jill graduated with distinction from Cornell University with a BS in electrical engineering and received her MBA from Stanford University.

Doug Williams

Chief Technology Officer

Doug Williams

Chief Technology Officer

Doug is responsible for leading the team that builds iSpecimen’s innovative, state-of-the-art cloud-based platform implemented at hospital and lab sites nationwide. By aggregating labs, biorepositories, and other organizations with access to human biospecimens  into one pool from which to pull, iSpecimen’s technology consolidates, sorts, and procures a wealth of specimens and data for the myriad organizations that need them, serving as a one-stop source for researchers at biotech, pharma, and academic institutions.

Doug has over 25 years of experience leading product development teams building market-leading web and mobile products for consumers and industry. Most recently, as Vice President of Engineering at FitnessKeeper, he realized his dream of developing software to help people stay fit and lead more active lives. With over 40 million users, FitnessKeeper has won Time’s Top 50 Apps twice. Prior to FitnessKeeper, Doug led the technology and product teams at numerous successful startups, including Zipcar, the world’s leading car-sharing network, and Family Education, the largest K-12 educational community. Doug has his Bachelor of Science degree in Electrical Engineering and Computer Science from Princeton University and his MBA from Harvard. He also holds three patents. Doug is passionate about fitness and has completed the Boston Marathon for Dana-Farber and the 150-mile Pan Mass Challenge and BikeMS rides to raise money for cancer and Multiple Sclerosis research.

David Wages, MD, PhD

Chief Medical Officer

David Wages, MD, PhD

Chief Medical Officer

David is responsible for ensuring that iSpecimen meets the medical research needs of customers. This includes ensuring that specimens are of the highest quality and that iSpecimen technology will continue to meet the increasingly sophisticated needs of the academic, pharmaceutical, and government research communities.

Prior to joining iSpecimen, David served as Senior Medical Director at Quintiles, the world’s largest clinical research organization, where he supported both large pharmaceutical companies as well as smaller biotech organizations in a wide variety of clinical oncology programs. David has worked in both start-up biotechs and large pharma. David began his career working on the clinical development of novel drug-device combinations for blood decontamination at Cerus Corporation. He then worked on clinical trials at Wyeth that led to the development of Xyntha®, a drug used to treat hemophilia. After a brief stint assisting institutional investors on healthcare technology opportunities at Leerink-Swann’s Medacorp, David then moved on to ARIAD Pharmaceuticals where he turned to cancer research, working on ARIAD’s mTOR inhibitor for solid tumors as well as initiating ARIAD’s phase I trial for chronic myeloid leukemia drug, Iclusig®. David next joined EMD Serono where he worked on phase I-III trials of immune-agents for oncology. David holds an MD and PhD from the University of Virginia School of Medicine where he focused on the basic science of oncology. He then completed a residency at the University of California, San Francisco and a fellowship in hematopathology at Boston’s Beth Israel hospital.

Eric Langlois

Eric Langlois

Vice President of Sales & Business Development

Eric Langlois

Eric Langlois

Vice President of Sales & Business Development

Eric is responsible for driving and managing all aspects of company sales and business development. In this position, he applies his strategic vision as well as day-to-day execution on initiatives related to revenue generation and account management.  He also plays a key role in analyzing and developing the supply partner network in order to meet the demands of iSpecimen’s rapidly expanding customer base.

Eric has amassed nearly 20 years of experience in the arena of preclinical sample collections and biobanking for translational research.  Before joining iSpecimen, Eric was Head of North American Sales for the ReproCell Group.  He helped build and manage a sales team driven by the demands of integrating four portfolio companies with products and services in Cellular Reprogramming, Stem Cells, 3D cell culture, and biospecimens.  Prior to that, he held rapidly increasing positions from Regional Sales Manager to VP of Sales with Genomics Collaborative, SeraCare Life Sciences, SeqWright, and BioServe.  For over a decade Eric and his teams have proven quite successful at driving revenue using a consultative, customer-centric approach.  Eric holds a BS in Biotechnology/Biochemistry from Worcester Polytechnic Institute.

Dawn Michelle

Dawn Michelle

Senior Director of Supply Operations

Dawn Michelle

Dawn Michelle

Senior Director of Supply Operations

Dawn and her team manage all aspects of supply operations at iSpecimen, from understanding researcher requirements through fulfillment, working closely with iSpecimen’s network of partner laboratories and biorepositories.

Dawn and her team are responsible for implementing iSpecimen’s technology at partner sites, ensuring each supplier’s data is properly harmonized to industry standards, and optimizing iSpecimen-related operations to run efficiently at each site.

Dawn has over 25 years of clinical laboratory management experience with an emphasis in regulatory oversight. Dawn was formerly the Director of Operations for the Partners Biorepository for Medical Discovery, where she was responsible for providing the Partners research community with a repository and related services to support clinical, translational, and basic science research programs. Prior to that she managed the implementation of a new laboratory information system for the blood transfusion service at Brigham and Women’s Hospital. She received a BS in Clinical Laboratory Science from Georgia State University earning MT(ASCP) certification. Later, she earned a Specialist in Blood Banking (SBB) certification. She holds an MS in Computer Information Systems from Boston University.

Kerry Norton

Kerry Norton

Senior Director of Business Planning and Analysis

Kerry Norton

Kerry Norton

Senior Director of Business Planning and Analysis

Kerry is responsible for finance, business analysis, and human resources at iSpecimen, with a heavy emphasis on financial operations and planning. As iSpecimen continues to grow, Kerry’s role is critical in ensuring agility, efficiency, and attraction of top talent. Her analytical acumen is invaluable in assessing state-of-the-business metrics, forecasting, and planning.

Prior to joining iSpecimen, Kerry held financial, analytical, and operational roles for more than ten years at companies including Datawatch, Altenex LLC (acquired by Edison International), and Empirix. She holds a Bachelor of Science and Business Management Degree from Babson College, where she concentrated in finance.

Brad Callow

Brad Callow

Director of Strategic Accounts

Brad Callow

Brad Callow

Director of Strategic Accounts

Brad is an integral part of the sales team, focused on strategic accounts. In this role, he is responsible for pursuing business in line with the company’s strategic plan and future vision. Brad also has experience handling finance and administration for iSpecimen, and over time has truly become the company’s culture czar.

Prior to iSpecimen, Brad was a Principal at Boston Millennia Partners, an early stage healthcare venture capital firm where he managed the deal flow team and assisted the firm in bringing multiple companies to exit. Prior to that, he worked in project management at Millennium Pharmaceuticals (acquired by Takeda) on multiple oncology drugs. Brad received his MBA from the Tuck School of Business at Dartmouth and received his BS from Tufts University.

Luis Nicolaou

Luis Nicolaou

Director of Product Management

Luis Nicolaou

Luis Nicolaou

Director of Product Management

Luis is responsible for driving all aspects of product management. He works with customers, partners, and the iSpecimen team to define and build the product offerings that deliver measurable benefits to all.

Luis has over 15 years of experience in the software industry spanning software development, professional services, and product management. He has held positions at start-ups for the majority of his career, contributing to their successful exits along the way. Luis earned his BS in Mathematics and Computer Science from Tufts University.

Jeffrey Goldman

Jeffrey Goldman

Director of Marketing

Jeffrey Goldman

Jeffrey Goldman

Director of Marketing

Jeff leads the marketing function at iSpecimen, driving growth through a strategic approach to digital marketing, public relations, content development, tradeshows and events, branding, and advertising.

Jeff has led strategy, marketing and product management programs for over 10 years in the life science industry at Thermo Fisher Scientific and Xcellerex, pre- and post-acquisition by GE Healthcare. Prior to his management roles, he was a drug discovery research scientist in molecular and cell biology at UCB Research and the Novartis Institutes for Biomedical Research. He has an MBA from Boston University and BA in biology from the University of Pennsylvania.

Emily Hubbard

Director of Site Management & Development

Emily Hubbard

Director of Site Management & Development

Emily leads the Site Development and Management Team at iSpecimen. The team works with clinical
sites to identify and audit clinical partners, facilitate agreements, implement workflow and compliance
measures as well as ongoing oversight of sites and protocols. This allows iSpecimen to access specimens
from patient populations our researchers require for their work.

Emily has worked in Life Sciences for 20 years. Her career began in molecular biology. She moved quickly
from the lab into management of Technical and Customer Support and Sales for companies such as
Research Genetics, Invitrogen/Life Technologies and Thermo Fisher Scientific. Emily shifted into clinical
research six years ago managing a team of Clinical Research Coordinators as well as management of
relationships at a vast network of Clinical Sites. She joined iSpecimen in 2016, based in
Huntsville, AL.

Board of Directors

In addition to our Founder & CEO, Christopher Ianelli and our COO, Jill Mullan, the following individuals sit on iSpecimen’s board of directors:

Andrew Ross

Board Member

Andrew Ross

Board Member

Andrew is a lifelong entrepreneur and private investor with a focus on early stage investments in biotechnology, collaborative consumption, and cause-focused enterprise.

George “Bud” Scholl

Board Member

Bud has been an entrepreneur for most of his professional life.  He has primarily focused on purchasing and working out distressed assets across a variety of industries and asset types. He has developed and invested in financial, real estate, service and technology companies. Bud currently serves as the President and Chief Executive Officer of OneBlood, which was formed in 2012 as a result of a merger he organized, when he was Chairman and CEO of the Community Blood Centers of Florida, one of the three largest blood centers in the southeastern United States. Bud also currently serves as the mayor of the City of Sunny Isles Beach, Florida, where he was elected in 2014 after serving as City Commissioner for seven years. Bud is a graduate of the University of Florida and holds an engineering degree in computer science. In his leisure time, Bud enjoys skiing, boating, restoring old games, and playing guitar.

Advisors

Robert Babkowski, MD, FCAP

Chair of Pathology, Stamford Hospital

Andy Brooks, PhD

Chief Operating Officer, Rutgers University Cell and DNA Repository

Martin Furgeson, PhD

Consultant, National Cancer Institute

Bill O’Donnell

Chief Executive Officer, Blade

Ed Trautman, PhD

VP, Informatics, Analytics and Business Intelligence LabCorp

Jim Vaught, PhD

Editor in Chief, Biopreservation & Biobanking Journal